MPG.eBooks - Search Results

Cover Image

1

An assessment of the SBIR program at the National Institutes of Health

by Wessner, Charles W.
Published 2009

National Academies Press

Cover Image

2

Venture funding and the NIH SBIR program

by Wessner, Charles W.
Published 2009

National Academies Press

Cover Image

3

CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: ankylosing spondylitis

Published 2020

CADTH

Cover Image

4

CADTH Canadian Drug Expert Committee recommendation: Belimumab (Benlysta subcutaneous [SC] -- GlaxoSmithKline Inc.) : indication: systemic lupus erythematosus (SLE)

Published 2020

CADTH

Cover Image

5

Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication: for the treatment of adult patients with active ankylosing spondylitis who have responded i...

Published 2020

CADTH

Cover Image

6

CADTH Canadian Drug Expert Committee recommendation: Dupilumab (Dupixent -- Sanofi-Aventis Canada Inc.) : indication: atopic dermatitis

Published 2020

CADTH

Cover Image

7

Pharmacoeconomic review report: Belimumab (Benlysta) (GlaxoSmithKline Inc.) : indication: indicated in addition to standard therapy for reducing disease activity in adult patients...

Published 2020

CADTH

Cover Image

8

Pharmacoeconomic report: Vedolizumab (Entyvio SC) Takeda Canada Inc. : indication : for the treatment of adult patients with moderately to severely active ulcerative colitis who ha...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Cover Image

9

High dose influenza vaccine for adults : a review of clinical effectiveness, cost-effectiveness, and guidelines

by Wells, Charlotte, Grobelna, Aleksandra
Published 2019

CADTH

Cover Image

10

Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : treatment of adult patients with active psoriatic arthritis who have responded inadequatel...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Cover Image

11

CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis

Published 2018

CADTH

Cover Image

12

Biologics versus immunomodulators or antibiotics for the management of fistulizing Crohn's disease : a review of comparative clinical effectiveness and cost-effectiveness

by Young, Calvin, Campbell, Kaitryn
Published 2019

CADTH

Cover Image

13

SBIR/STTR at the National Institutes of Health

Published 2015

The National Academies Press

Cover Image

14

CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis

Published 2016

Canadian Agency for Drugs and Technologies in Health

Cover Image

15

CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: ankylosing spondylitis

Published 2020

CADTH

Cover Image

16

CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple...

Published 2017

Canadian Agency for Drugs and Technologies in Health

Cover Image

17

Pharmacoeconomic review report: Tocilizumab (Actemra) (Hoffman-La Roche Limited)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Cover Image

18

Pharmacoeconomic report: Ofatumumab (Kesimpta) (Novartis Pharmaceuticals Canada Inc.) : indication: multiple sclerosis, relapsing-remitting

Published 2021

Canadian Agency for Drugs and Technologies in Health

Cover Image

19

CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis

Published 2016

Canadian Agency for Drugs and Technologies in Health

Cover Image

20

CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis

Published 2018

CADTH

1
2